management team

Bill R. Sanford, Chairman and Chief Executive Officer

“I am very proud of the achievements of the Imalux team of clinicians, engineers, and scientists. They have successfully developed and packaged the highly sophisticated OCT technology in a compact, easy-to-use, point of care system that provides real-time, high resolution imaging in a variety of clinical settings. The significant clinical benefits of use of our Niris Imaging System are already being recognized by international leaders in a variety of urology, gynecology, gastroenterology, and ENT surgical and diagnostic applications.”

Bill R. Sanford is Founder and Chairman of Symark LLC, a private equity, technology commercialization, and business development organization. He is also Executive Founder and retired Chairman of the Board, President, and Chief Executive Officer of Steris Corporation (NYSE:STE), a global leader in infection and contamination prevention systems, products, services, and technologies. He serves as Chairman of Greatbatch, Inc. (NYSE:GB) and as a Board Member of KeyCorp (NYSE:KEY), Cleveland Clinic, BioEnterprise Corporation, Kansas Bioscience Authority, and several early and growth stage technology companies and investment partnerships.

Mr. Sanford is an experienced entrepreneur, executive, consultant, investor, and board member with extensive new venture, merger and acquisition, turnaround, senior management, and market development experience. His business career has focused on the development and commercialization of bioscience products, health services, advanced information systems, and other innovative technology applications. He holds several patents and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

 

Paul G. Amazeen, Ph.D., Executive VP and Chief Technology Officer

	“Having been involved in the successful commercialization of several technologies, I am excited about what we have here. OCT offers distinct advantages as compared to the other imaging modalities.”

For over 20 years, Dr. Amazeen has been a senior executive developing medical products. His background includes general and corporate management responsibilities with special emphasis on technology, business strategic planning, and new product development from concept through marketing and sales. He held positions of technical management at the Raytheon Company (nuclear medicine) and for General Electric’s first three ultrasound products. He was the Director of Operations for Rohe Scientific Corporation, which successfully developed and marketed the industry’s first grayscale ultrasound machine. He founded Sound Imaging, Inc., which developed a new, patented ultrasound transducer technology and imaging instrument.

 

Thomas F. Barnish, Vice President and Chief Financial Officer

	"OCT has the potential to help patients through early detection of disease and efficient removal of dangerous tissue during surgery. Our investors have provided the Company with a sound capital base on which to help commercialize the technology."

Mr. Barnish has over 25 years of experience in executive finance positions with bioscience companies including Medeva Pharmaceuticals, Gliatech, and Copernicus Therapeutics. He has multi-industry experience in manufacturing, distribution, and retailing, with an emphasis on asset management and cost containment. Mr. Barnish has a successful record of accomplishment in large and small company work environments, both public and private, with particular strengths in financing, administration, systems development, treasury functions, compliance reporting, acquisitions and divestitures.

 

Nancy J. Tresser, M.D., M.B.A., Vice President and Chief Medical Officer

"The Niris Imaging System will prove to be a welcome addition to many medical disciplines that benefit from real-time information. Physicians will be guided by on-demand, real-time tissue microstructure imaging. Patients will benefit from this non-invasive method that enables their physician to biopsy with increased accuracy. Patients will also appreciate the effect Niris can have on organ-sparing procedures; it will help to decrease the risk of local recurrence, while increasing the amount of organ residual in select cases. I believe that the clinical and research applications to which Niris can be applied are limited only by our imagination."

Dr. Tresser has over 15 years of experience in the medical field in various settings including academics, government and private practice. Her impressive background includes experience at the National Institutes of Health, National Institute of Neurological Disorders and Stroke, Office of the Clinical Director, in Bethesda, Maryland, where she served as Special Expert, Neuropathologist. Dr. Tresser has held the title of Assistant Professor of Pathology at the University of South Florida and University Hospitals of Cleveland/Case Western Reserve University School of Medicine. Additional past experience includes serving as Staff Neuropathologist at the James A. Haley VA Medical Center and the H. Lee Moffitt Cancer Center, both located in Tampa, Florida. Dr. Tresser has contributed to over 50 medical publications and presentations.